Siponimod exerts neuroprotective effects on the retina and higher visual pathway through neuronal S1PR1 in experimental glaucoma.
glaucoma
intraocular pressure
neurodegeneration
neuroprotection
optic nerve injury
retinal ganglion cells
siponimod
sphingosine-1-phosphate
Journal
Neural regeneration research
ISSN: 1673-5374
Titre abrégé: Neural Regen Res
Pays: India
ID NLM: 101316351
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
entrez:
7
10
2022
pubmed:
8
10
2022
medline:
8
10
2022
Statut:
ppublish
Résumé
Sphingosine-1-phosphate receptor (S1PR) signaling regulates diverse pathophysiological processes in the central nervous system. The role of S1PR signaling in neurodegenerative conditions is still largely unidentified. Siponimod is a specific modulator of S1P1 and S1P5 receptors, an immunosuppressant drug for managing secondary progressive multiple sclerosis. We investigated its neuroprotective properties in vivo on the retina and the brain in an optic nerve injury model induced by a chronic increase in intraocular pressure or acute N-methyl-D-aspartate excitotoxicity. Neuronal-specific deletion of sphingosine-1-phosphate receptor (S1PR1) was carried out by expressing AAV-PHP.eB-Cre recombinase under Syn1 promoter in S1PR1
Identifiants
pubmed: 36204852
pii: NeuralRegenRes_2023_18_4_840_344952
doi: 10.4103/1673-5374.344952
pmc: PMC9700103
doi:
Types de publication
Journal Article
Langues
eng
Pagination
840-848Déclaration de conflit d'intérêts
None
Références
J Neuroimmunol. 2013 Mar 15;256(1-2):13-8
pubmed: 23290828
Neuron. 2018 Feb 21;97(4):742-768
pubmed: 29470968
Eye (Lond). 2020 Aug;34(8):1371-1379
pubmed: 32071402
JAKSTAT. 2013 Jan 1;2(1):e22925
pubmed: 24058789
Int J Mol Sci. 2020 Oct 13;21(20):
pubmed: 33066042
Invest Ophthalmol Vis Sci. 2014 Apr 17;55(5):3060-6
pubmed: 24744204
Mol Ther. 2019 Feb 6;27(2):424-441
pubmed: 30341011
Neuron. 2009 Dec 10;64(5):617-23
pubmed: 20005819
Arch Neurol. 2005 Sep;62(9):1345-56
pubmed: 16157741
Drug Des Devel Ther. 2017 Nov 02;11:3153-3157
pubmed: 29138536
Curr Neurol Neurosci Rep. 2021 Apr 9;21(6):26
pubmed: 33835275
Brain. 2019 Feb 1;142(2):426-442
pubmed: 30668642
Science. 2019 Oct 18;366(6463):
pubmed: 31624181
Invest Ophthalmol Vis Sci. 2003 Jan;44(1):154-9
pubmed: 12506068
Rev Neurosci. 2013;24(3):301-21
pubmed: 23612594
Prog Brain Res. 2008;173:465-78
pubmed: 18929128
Nat Commun. 2014 Sep 25;5:4859
pubmed: 25255053
Lancet. 2018 Mar 31;391(10127):1263-1273
pubmed: 29576505
Neural Plast. 2016;2016:8072156
pubmed: 28018679
Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5403-20
pubmed: 20980702
Nat Rev Neurol. 2013 Jan;9(1):44-53
pubmed: 23165340
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:149-170
pubmed: 30625282
Lancet. 2017 Nov 11;390(10108):2183-2193
pubmed: 28577860
Cells. 2020 Jun 22;9(6):
pubmed: 32580348
Front Mol Neurosci. 2018 Aug 24;11:293
pubmed: 30197586
Pharmaceutics. 2021 Jan 15;13(1):
pubmed: 33467779
Curr Top Microbiol Immunol. 2014;378:149-70
pubmed: 24728597
Exp Neurol. 2019 Apr;314:111-125
pubmed: 30703361
Prog Retin Eye Res. 2020 Mar;75:100799
pubmed: 31557521
Expert Opin Pharmacother. 2019 Feb;20(2):143-150
pubmed: 30517042
Pharmacol Res. 2016 Sep;111:713-720
pubmed: 27475885
Front Immunol. 2020 Apr 08;11:635
pubmed: 32322257
Neuropharmacology. 2017 Feb;113(Pt B):597-607
pubmed: 27825807
Stroke. 2017 Dec;48(12):3336-3346
pubmed: 29114096
Nat Neurosci. 2017 Aug;20(8):1172-1179
pubmed: 28671695
Front Neurol. 2021 Feb 04;11:612422
pubmed: 33613418
J Neurosci. 2006 Dec 6;26(49):12633-41
pubmed: 17151265
Invest Ophthalmol Vis Sci. 2012 Mar 09;53(3):1271-5
pubmed: 22222509
Neuropharmacology. 2018 Jun;135:139-150
pubmed: 29481916
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2012-2017
pubmed: 28167760
Front Neurol. 2021 May 14;12:654850
pubmed: 34054698
Hum Mol Genet. 2015 Sep 1;24(17):4958-70
pubmed: 26063761
Brain Res Bull. 2020 Nov;164:75-82
pubmed: 32846199
Mol Cell Biol. 2005 Dec;25(24):11113-21
pubmed: 16314531
FASEB J. 2017 Jan;31(1):172-179
pubmed: 27671228
Cells. 2019 Jan 07;8(1):
pubmed: 30621015
Exp Eye Res. 2007 Jan;84(1):176-84
pubmed: 17094963
Cells. 2020 Feb 25;9(3):
pubmed: 32106630
Cells. 2020 Apr 29;9(5):
pubmed: 32365642
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6
pubmed: 21177428
N Engl J Med. 2006 Sep 14;355(11):1124-40
pubmed: 16971719
J Neurochem. 2016 Aug;138(4):571-86
pubmed: 27309795
Cell Biosci. 2020 Apr 1;10(1):54
pubmed: 32266056
CNS Drugs. 2016 Feb;30(2):135-47
pubmed: 26715391
Acta Neuropathol. 2011 Jun;121(6):737-51
pubmed: 21311901
Mol Neurobiol. 2020 Sep;57(9):3759-3784
pubmed: 32578008
Exp Eye Res. 2012 Oct;103:119-20
pubmed: 22001715
Neurobiol Aging. 2017 May;53:181-191
pubmed: 28262325
Neurotox Res. 2019 Apr;35(3):775-795
pubmed: 30707354
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Theranostics. 2021 Apr 15;11(13):6154-6172
pubmed: 33995651
Cells. 2020 Jul 24;9(8):
pubmed: 32722245
Glia. 2010 May;58(7):780-9
pubmed: 20091782
EMBO Mol Med. 2019 Aug;11(8):e10291
pubmed: 31318166
Molecules. 2017 Feb 23;22(3):
pubmed: 28241498
Mult Scler J Exp Transl Clin. 2021 Nov 03;7(4):20552173211049168
pubmed: 34777855
Prog Neurobiol. 2020 Oct;193:101817
pubmed: 32360241
Cells. 2021 Nov 18;10(11):
pubmed: 34831439
Curr Drug Targets. 2016;17(16):1841-1850
pubmed: 26424391
Biochim Biophys Acta Biomembr. 2017 Sep;1859(9 Pt B):1573-1582
pubmed: 28315304
J Cell Biochem. 2020 Jul 21;:
pubmed: 32692886
Stroke. 2010 Feb;41(2):368-74
pubmed: 19940275